Treatment Options for Polycystic Ovary Syndrome (PCOS)
Lifestyle modifications are the first-line therapy for PCOS management, focusing on dietary changes and physical activity to improve metabolic and reproductive outcomes. 1
First-Line Interventions
Lifestyle Modifications
Dietary Recommendations:
- Energy deficit of 30% or 500-750 kcal/day
- Daily caloric intake of 1,200-1,500 kcal/day
- Low glycemic index foods
- Anti-inflammatory diet pattern
- Adequate magnesium and zinc intake 1
Physical Activity Guidelines:
- For general health: 150+ minutes/week of moderate activity or 75+ minutes/week of vigorous activity
- For weight loss: 250+ minutes/week of moderate activity or 150+ minutes/week of vigorous activity
- Include muscle-strengthening activities 2 days/week
- Target 10,000 steps daily and minimize sedentary time 1
Even modest weight loss (5% of initial weight) can significantly improve metabolic and reproductive abnormalities in PCOS 1, 2
Pharmacological Interventions
For Menstrual Irregularities and Hyperandrogenism
- Combined oral contraceptives (COCs): First-line treatment for menstrual irregularities and acne 1
- Anti-androgens: For hirsutism resistant to first-line treatments
- Options include spironolactone, flutamide, and finasteride 1
For Insulin Resistance
- Metformin: First-line pharmacological intervention for insulin resistance in PCOS
- Particularly beneficial for adolescents and women with type 2 diabetes 1
- GLP-1 receptor agonists (liraglutide, semaglutide): May improve anthropometric outcomes in PCOS patients with obesity 1
For Fertility Treatment
- Clomiphene citrate: First-line treatment for ovulation induction
- Approximately 80% of PCOS patients ovulate with this treatment, and half of these conceive 1
- Caution: Monitor for Ovarian Hyperstimulation Syndrome (OHSS), especially in PCOS patients who are unusually sensitive to gonadotropins 3
- Early warning signs of OHSS include abdominal pain and distention, nausea, vomiting, diarrhea, and weight gain 3
- Use the lowest effective dose and provide close monitoring 3
- Low-dose gonadotropin therapy: Recommended if clomiphene fails 1
Monitoring and Assessment
Initial Evaluation
Metabolic screening:
- Two-hour oral glucose tolerance test (75g glucose load)
- Fasting lipid profile (total cholesterol, LDL, HDL, triglycerides)
- BMI calculation with waist-hip ratio measurement 1
Hormonal evaluation:
- Total testosterone or bioavailable/free testosterone levels
- Thyroid-stimulating hormone (TSH) levels
- Prolactin levels 1
Ongoing Monitoring
- Annual metabolic screening for women with irregular cycles
- Monitor for endometrial hyperplasia in women with irregular cycles
- Regular assessment of weight, waist circumference, menstrual cycles
- Annual assessment of metabolic parameters, including insulin resistance markers, lipid profile, and blood pressure 1
- Screening for anxiety and depression 1
Special Considerations
Ethnic-Specific Approach
- Consider ethnic-specific BMI and waist circumference categories
- Ethnic groups with PCOS at high cardiometabolic risk require greater attention to lifestyle interventions 1
Potential Complications
- With clomiphene citrate therapy, monitor for visual symptoms (blurring, scotomata)
- Discontinue treatment and perform ophthalmological evaluation if visual symptoms occur 3
- Monitor for OHSS, which can progress rapidly and become a serious medical disorder
- Symptoms include ovarian enlargement, gastrointestinal symptoms, ascites, dyspnea, oliguria, and pleural effusion 3
Treatment Algorithm
- Start with lifestyle modifications for all PCOS patients
- Add pharmacological therapy based on predominant symptoms:
- For menstrual irregularities/hyperandrogenism → COCs
- For insulin resistance → Metformin
- For fertility → Clomiphene citrate (with careful monitoring)
- Consider second-line therapies if first-line treatments fail:
- Anti-androgens for persistent hirsutism
- Gonadotropins for clomiphene resistance
Remember that PCOS management requires a comprehensive approach addressing both the immediate symptoms and the long-term metabolic and reproductive health risks.